Omics! Omics!

A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery

Friday, December 21, 2012

Not Exactly the First Tuesday After the First Monday of November

›
This past presidential election was as nasty as any in recent memory, and so perhaps folks are reviewing their support for Churchill's d...
1 comment:
Wednesday, December 19, 2012

MUSKET then FLASH, vice versa or just COPE with it?

›
It's gratifying to see that yesterday's The Trouble with FASTQ item gathered a number of lively comments, and there are certainly a...
2 comments:
Tuesday, December 18, 2012

The Trouble with FASTQ

›
I spend a lot of time working with sequencing data, and the most common format for such data is FASTQ.  FASTQ has many things to appreciat...
11 comments:
Monday, November 26, 2012

Scribl is Neat!

›
Speaking of Twitter , one thing I've found it highly valuable for is discovering new tools and ideas in the bioinformatics space.  It...

BTW, I'm on Twitter

›
For a long while, my only interaction with Twitter was to monitor key hashtags during AGBT and ASHG.  However, I've gotten myself sucked...
1 comment:
Tuesday, November 13, 2012

Why Next Gen Now?

›
A confession: I've considered writing this piece for a lot of years now; not quite as many as this space has existed, but many years.  S...
9 comments:
Sunday, October 21, 2012

Nanopores: Fission or Fusion?

›
It's fall, and the foliage in New England is putting on its usual spectacular show.  What isn't showing is any of the progress in na...
6 comments:
Wednesday, September 19, 2012

Does Illumina Have A Sequence Diversity Problem?

›
Roughly speaking, NGS sample preparation workflows can be split into two basic classes of workflows.  Complete molecule workflows are curren...
10 comments:
Monday, September 17, 2012

BGI Gobbles Complete Genomics

›
An email this morning alerted me that BGI Shenzhen is acquiring Complete Genomics.  I hadn't been following Complete's business very...
6 comments:
Wednesday, September 12, 2012

Shameless cancer quacks

›
A news item meant to shock its readers caught my eye, but in the end I was shocked and sickened in a way that I think lay far beyond the wri...
1 comment:
Sunday, September 09, 2012

Is Cambridge Almost Full?

›
If you tour around the extended Kendall Square area of Cambridge, you'll find a number of large construction sites.  Various projects fo...
1 comment:
Tuesday, August 28, 2012

Farewell to a Giant Leaper

›
When I was a boy, a nearly annual occurrence was a trip to Kentucky to my maternal grandparents' house.  My biological grandmother died ...
Saturday, August 25, 2012

Owning a Sequencer is NOT a Prerequisite for Sequencing!

›
Besides the l ittle cancer genomics piece yesterday, another genomics paper getting quite a bit of popular press attention is the nice work...
3 comments:
Friday, August 24, 2012

The Perils of the Too Small Gene Panel

›
The newswires are alive with summaries of an item in Science Express which, discounting the supplementary material, isn't much bigger t...
2 comments:
Tuesday, August 14, 2012

Jackalopes & Guest Posts

›
Recently, the topic of jackalopes showed up at work.  Anyone who has toured the American West has probably come across postcards of these c...
3 comments:
Tuesday, August 07, 2012

An unconvincing case to X-out algebra

›
I had a bit of a long commute yesterday, driving from south-central New Jersey up to Starbase Cambridge.  In general it's a dull ride, h...
4 comments:
Thursday, July 12, 2012

Complete Genomics Goes Long

›
In Nature this week (as an open access article!) is a report from Complete Genomics and collaborators describing CG's new "Long Fr...
Tuesday, June 26, 2012

Qiagen Buys A Sequencer

›
Today's news (take your pick of Bio-IT or GenomeWeb  for original stories) is that Qiagen has bought out Intelligent Biosystems (IBS), ...
1 comment:
Tuesday, June 19, 2012

Out Damned Spot Instance! Out I say!

›
A piece of advice for anyone in the bioinformatics world: get working knowledge of the Amazon EC2 cloud computing system.  Now, there is a ...
7 comments:
Friday, June 15, 2012

States Funding Companies: Always a Bad Idea

›
The annual BIO meeting will be in Boston next week, so the media is looking a little bit more at our sector.  Today's Globe has an Op-Ed...
‹
›
Home
View web version

About Me

My photo
Keith Robison
Dr. Robison spent 10 years at Millennium Pharmaceuticals working with various genomics & proteomics technologies & working on multiple teams attempting to apply these throughout the drug discovery process. He spent 2 years at Codon Devices working on a variety of protein & metabolic engineering projects as well as monitoring a high-throughput gene synthesis facility. After a brief bit of consulting, he rejoined the cancer drug discovery field at Infinity Pharmaceuticals in May 2009. In September 2011 he joined Warp Drive Bio, a startup applying genomics to natural product drug discovery. In February 2019 he joined Ginkgo Bioworks, a synthetic biology company. Other recurring characters in this blog are his late loyal Shih Tzu Amanda, his current Shih Poo Lily and his now adult son alias TNG (The Next Generation). Dr. Robison can be reached via his Gmail account, keith.e.robison@gmail.com You can also follow him on Twitter as @OmicsOmicsBlog.
View my complete profile
Powered by Blogger.